{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:45:54Z","timestamp":1769165154471,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.09.023","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:50:06Z","timestamp":1758023406000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug reaction with eosinophilia and systemic symptoms syndrome in association with novel antineoplastic pharmacotherapy: Characterizing reported clinical patterns and outcomes utilizing the Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.1016","author":[{"given":"Aryan","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav N.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babar K.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2025.09.023_bib1","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2025.09.023_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.023_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.023_bib4","article-title":"Reactivation of human herpesvirus (HHV) 6 as etiology of acute liver injury in drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report","volume":"14","author":"Li","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.023_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0018578717717394","article-title":"Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide","volume":"52","author":"Shanbhag","year":"2017","journal-title":"Hosp Pharm"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:27:33Z","timestamp":1765960053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225028075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":5,"alternative-id":["S0190962225028075"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug reaction with eosinophilia and systemic symptoms syndrome in association with novel antineoplastic pharmacotherapy: Characterizing reported clinical patterns and outcomes utilizing the Food and Drug Administration Adverse Event Reporting System database","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}